Measures of atrophy in the whole brain can reliably assess treatment effect in clinical trials of patients with multiple sclerosis (MS). Trials assessing the effect of treatment on grey matter (GM) and white matter (WM) atrophy are very informative, but hindered by technical limitations. This study used a robust longitudinal method to measure...
-
2022 (v1)PublicationUploaded on: February 11, 2024
-
2023 (v1)Publication
Importance: Multiple sclerosis (MS) misdiagnosis remains an important issue in clinical practice. Objective: To quantify the performance of cortical lesions (CLs) and central vein sign (CVS) in distinguishing MS from other conditions showing brain lesions on magnetic resonance imaging (MRI). Design, setting, and participants: This was a...
Uploaded on: February 13, 2024